P040 The cytokine milieu in patients with inflammatory bowel disease impacts the phenotype of mesenchymal stromal cells
M. Barnhoorn*1, K. Schepers2, H. Verspaget1, W. Fibbe2, L. Hawinkels1, M. van Pel2, A. van der Meulen - de Jong1
1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands, 2Leiden University Medical Center, Immunohematology and Blood Transfusion, Leiden, The Netherlands
Mesenchymal stromal cells (MSCs) have the capacity to promote healing of refractory perianal fistulas in Crohn’s disease (CD) and pre-treatment with cytokines may enhance therapeutic efficacy. Furthermore, locally applied MSCs are under clinical development for treatment of refractory proctitis in ulcerative colitis (UC). Despite these clinical advances, the mechanism of action of MSC therapy is largely unknown. We hypothesise that the proinflammatory environment in the patient promotes the immunomodulatory properties of MSCs. Therefore, we analysed cytokine levels in inflamed tissues obtained from CD and UC patients. Next, we assessed the expression of immunomodulatory molecules by MSCs upon exposure to these cytokines.
U-plex cytokine assay and ELISA were used to measure the levels of 11 cytokines, including interferon-γ, interleukin (IL)-17 and IL-1β, in perianal fistula scraping of patients with CD (
Scrapings of perianal fistulas obtained from CD patients contained high levels of cytokines, including IL-1β and IL-17 (IL-1β 0.102 pg/µg vs. 0.012 pg/µg in normal colon tissue,
The patient’s proinflammatory milieu is strongly dependent on the underlying disease. We found